secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001021771-24-000195
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement
--------------------------------------------------------------------------------

- Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
- Cash & equivalents $13.1M, no debt as of Sep 30, 2024.
- $230,700 product revenue from Cartessa Aesthetics supply agreement in Q3.
- Blinded Phase 2 data: 70% of 10 patients at 26 wks had >30% pain reduction, >30% function increase.
- No SAEs or dose-limiting toxicity at 26–52 wks; provisional NYSDOH license for allogeneic processing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000195/0001021771-24-000195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000195/brt8k111224.htm
  HTML page:      https://secwatch.observer/filing/0001021771-24-000195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer